Andrew W Pippas
Overview
Explore the profile of Andrew W Pippas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
709
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flanagan K, Earls J, Hiken J, Wellinghoff R, Ponder M, McLeod H, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39489541
Background: Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for...
2.
Hoin J, Carthon B, Brown S, Durham L, Garrot L, Ghamande S, et al.
Front Health Serv
. 2024 Mar;
4:1254294.
PMID: 38523649
The Georgia Center for Oncology Research and Education (Georgia CORE) and the Georgia Society of Clinical Oncology (GASCO) held a one-day summit exploring opportunities and evidence-based interventions to address disparities...
3.
Flanagan K, Earls J, Schillebeeckx I, Hiken J, Wellinghoff R, LaFranzo N, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(15):14125-14136.
PMID: 37552307
Purpose: Anti-PD-1 therapy provides clinical benefit in 40-50% of patients with relapsed and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC). Selection of anti- PD-1 therapy is typically based on...
4.
Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.
N Engl J Med
. 2021 Jun;
384(25):2394-2405.
PMID: 34081848
Background: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with or germline mutation-associated early...
5.
Lenz H, Van Cutsem E, Khambata-Ford S, Mayer R, Gold P, Stella P, et al.
J Clin Oncol
. 2006 Oct;
24(30):4914-21.
PMID: 17050875
Purpose: This multicenter study evaluated the antitumor activity of cetuximab, an immunoglobulin G1 antibody directed at the epidermal growth factor receptor (EGFR), in metastatic colorectal carcinoma (CRC) refractory to irinotecan,...
6.
Jakub J, Drake F, Pippas A, Gardner M, Fraile R, Giuliano R, et al.
Cancer Control
. 2003 Oct;
10(5):411-3.
PMID: 14581896
No abstract available.